Immutep Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
News Jun 27, 2008
Immutep S.A., a biopharmaceutical company specialized in immunostimulatory and immunomodulatory treatments of cancer and infectious or autoimmune disease, announced the publication of research conducted by Cell Genesys, Inc. showing that a lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell immunotherapy. These data were published in the June issue of Clinical Cancer Research.
The research team found that combining mLAG-3Ig with a murine GM-CSF-secreting tumor cell immunotherapy prolonged the survival of tumor-bearing animals compared to animals treated with either therapy alone.
Prolonged survival correlated with increased numbers of systemic IFN gamma-secreting CD8+ T-cells and a significantly increased infiltration of activated effector CD8+ T-cells into the tumor.
The mLAG-3Ig fusion protein is a murine homologue of Immutep's lead product ImmuFact® IMP321, a potent natural human immunostimulatory factor designed to amplify the T cell immune response.
IMP321 can be used either as an immunopotentiator in therapeutic vaccines or alone at higher doses as a monotherapy or in combination with chemotherapy. Six clinical trials have been initiated with ImmuFact IMP321 in the last three years.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018